## ADPT: Adaptive Biotechnologies Corpor - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 4.6% in mid entry zone (3.0-6.0%), top 5% cross-sectional ranking. Caution: MRS_5 (-5.4%) diverging from MRS_10, watch for reversal. Outperforming sector by 3.2%. Caution: momentum weakening (-26.4% MRS).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($16.64)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-11 | Morgan Stanley | $16 | $11 | +45% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-11 | Morgan Stanley | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($1.13M) |
| Sells | 11 ($5.21M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Viking Global Invest: 19.7% (0.0%)
- Blackrock Inc.: 8.8% (-2.3%)
- Vanguard Group Inc: 7.4% (-0.0%)
- Ameriprise Financial: 3.9% (+84.3%)
- Sumitomo Mitsui Trus: 2.4% (-15.1%)

### Key Risks

1. High beta (2.20) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Insider selling cluster: $5.2M in recent transactions.
3. Elevated short interest (8.7%): bears positioning against stock.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.57 indicates undervaluation relative to growth. Balance sheet: strong liquidity (3.4x). Analyst sentiment positive (1 raises, avg +45%). Insider selling cluster ($5.2M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.4B |
| Beta | 2.20 |
| 52W Range | $5.80 - $20.76 |
| Short Interest | 8.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.57 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 deteriorating from 31.0% to 4.6% (-26.4% in 5 days), indicating relative weakness vs NASDAQ. Currently in upper STRENGTH zone (3.0-6.0%), cross-sectional ranking at 94th percentile. MRS_5 (-5.4%) diverging from MRS_10 - short-term weakness emerging. Outperforming sector by 3.2pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 4.57% (CS: 95) | Strong |
| RSI_14 | 61.6 | Neutral |
| MACD Histogram | 0.46 | Bullish |
| vs SMA20 | 1.139x | Above |
| vs SMA50 | 1.181x | Above |
| vs SMA200 | 1.645x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $18.84
- **Stop Loss:** $16.64 (11.7% risk)
- **Target:** $22.14 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 340
- **Position Value:** $6,405.60
- **Portfolio %:** 6.41%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-10 (Est: $-0.18)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.14 | $0.06 | +143.3% |
| 2025Q2 | $-0.24 | $-0.17 | +28.6% |
| 2025Q1 | $-0.31 | $-0.20 | +35.5% |
| 2024Q4 | $-0.24 | $-0.23 | +5.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*